Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016:2016:4759040.
doi: 10.1155/2016/4759040. Epub 2016 May 17.

Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis

Affiliations
Comparative Study

Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis

Kosuke Hamai et al. Dis Markers. 2016.

Abstract

Background. Recent reports indicate that matrix metalloproteinase-7 (MMP-7) and CC-chemokine ligand 18 (CCL18) are potential disease markers of idiopathic pulmonary fibrosis (IPF). The objective of this study was to perform direct comparisons of these two biomarkers with three well-investigated serum markers of IPF, Krebs von den Lungen-6 (KL-6), surfactant protein-A (SP-A), and SP-D. Methods. The serum levels of MMP-7, CCL18, KL-6, SP-A, and SP-D were evaluated in 65 patients with IPF, 31 patients with bacterial pneumonia, and 101 healthy controls. The prognostic performance of these five biomarkers was evaluated in patients with IPF. Results. The serum levels of MMP-7, KL-6, and SP-D in patients with IPF were significantly elevated compared to those in patients with bacterial pneumonia and in the healthy controls. Multivariate survival analysis showed that serum MMP-7 and KL-6 levels were independent predictors in IPF patients. Moreover, elevated levels of both KL-6 and MMP-7 were associated with poorer survival rates in IPF patients, and the combination of both markers provided the best risk discrimination using the C statistic. Conclusions. The present results indicated that MMP-7 and KL-6 were promising prognostic markers of IPF, and the combination of the two markers might improve survival prediction in patients with IPF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serum levels of (a) MMP-7, (b) CCL18, (c) KL-6, (d) SP-A, and (e) SP-D in patients with IPF, those with bacterial pneumonia (BP), and healthy controls (HC). The significant differences between the three groups were evaluated using Bonferroni's test ( p < 0.01 and ∗∗ p < 0.001).
Figure 2
Figure 2
ROC curve analysis in five biomarkers to distinguish IPF patients from control subjects which consisted of patients with bacterial pneumonia and healthy controls.
Figure 3
Figure 3
Kaplan-Meier analysis to evaluate the probability of 5-year survival among the three groups which were divided according to the serum levels of KL-6 and MMP-7. The cut-off levels of KL-6 and MMP-7 were 1040 U/mL and 9.67 ng/mL, respectively. The probability of 5-year survival was significantly different among them (p = 0.0004).

Similar articles

Cited by

References

    1. Raghu G., Collard H. R., Egan J. J., et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine. 2011;183(6):788–824. doi: 10.1164/rccm.2009-040gl. - DOI - PMC - PubMed
    1. Schwartz D. A., Helmers R. A., Galvin J. R., et al. Determinants of survival in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine. 1994;149(2, part 1):450–454. doi: 10.1164/ajrccm.149.2.8306044. - DOI - PubMed
    1. King T. E., Jr., Tooze J. A., Schwarz M. I., Brown K. R., Cherniack R. M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. American Journal of Respiratory and Critical Care Medicine. 2001;164(7):1171–1181. doi: 10.1164/ajrccm.164.7.2003140. - DOI - PubMed
    1. Kohno N., Kyoizumi S., Awaya Y., Fukuhara H., Yamakido M., Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96(1):68–73. doi: 10.1378/chest.96.1.68. - DOI - PubMed
    1. Kohno N., Awaya Y., Oyama T., et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. American Review of Respiratory Disease. 1993;148(3):637–642. doi: 10.1164/ajrccm/148.3.637. - DOI - PubMed

Publication types

MeSH terms